Research Study to Look at How Well Semaglutide Works in People Living With Heart Failure, Obesity and Type 2 Diabetes
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 617 participants.
Also called NCT04916470
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 617 participants
- Sponsor
- Registry
-
NCT04916470 -
2020-004170-22
-
- Other papers using this trial's data
- Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes
- Semaglutide in obesity-related heart failure with preserved ejection fraction and type 2 diabetes across baseline HbA1c levels (STEP-HFpEF DM): a prespecified analysis of heart failure and metabolic outcomes from a randomised, placebo-controlled trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Argentina, Austria, Canada, Czechia, Germany, Hungary, India, Israel, Italy, Japan, Netherlands, Poland, Spain, Sweden, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT04916470. Randomized; quadruple masking; primary purpose treatment. Start 2021-06-15 (actual); primary completion 2023-10-11 (actual). Results posted on 2026-11-02.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Research Study to Look at How Well Semaglutide Works in People Living With Heart Failure, Obesity and Type 2 Diabetes
- Acronym
- STEP HFpEF DM
- Condition
- Heart Failure With Preserved Ejection Fraction (HFpEF) and Diabetes Mellitus, Type 2
- Intervention (Drug)
- Semaglutide
- Intervention (Drug)
- Placebo (Semaglutide)
- Lead sponsor
- Novo Nordisk A/S
Record details
- Record id
cardio:ct-nct04916470- Content hash
cc9990d048dd38929da2e29618f42dc14f49c46eb76475abb81ed97713893232